Magnetic Group Signaling (MGS®) standardizes NMR systems and sample processing to ensure reproducible results on different NMR instruments.
Advanced. Automated. Affordable. Mastering Metabolite Networks for Real-Time Precision Medicine.
Learn more
AXINON® is the first modular software-based system providing hardware, operating system, MGS® processor and individual test applications.
Locations: Boston, MA;
Regensburg, GE
employees of medical and
scientific disciplines
Founded as a spin-off of
Regensburg University
analyses worldwide with numares
technology
We focus on the discovery, development and commercialization of diagnostic tests, using metabolite constellations to solve unmet medical needs that cannot be addressed by single biomarker-based medicine.
Numares has developed a versatile platform technology for developing innovative diagnostic tests based on differences in the metabolism of people with and without a particular disease.
Our diagnostic tests are based on the interpretation of biomarkers in the metabolism, with dynamics and relation to each other enabling the prediction of disease progression. These metabolite constellations create diagnostics of a new generation: non-invasive, timely and meaningful, at manageable costs.
- Chairman, Supervisory Board
- Managing Partner, SHS Capital
- More than 20 years’ experience in private equity
- Former CEO at numares
- Previously with Roche and McKinsey
- Previously Managing Director of Mayfair SE
- Previously board member at Tchibo
- Supervisory board member at Puma
- Previously Senior Director at Mayo Clinic
- Steering committee member of numares-Mayo collaboration
- Previously with Oncospire Genetics and Roche
- Founder and CEO of DiaMedCare
- Previously with Novartis Ciba Geigy
- Previously with McKinsey
- Founder and CEO of kineo finance AG (formerly DiaMedCare AG)
- Scientific Advisory Board of Everly Health
- Strategic and scientific advisor
- Previously with Roche and Illumina